A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 01 Sep 2021
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms aboundsqm
- Sponsors Celgene Corporation
- 29 Aug 2021 This trial has been discontinued in Italy.
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer.
- 20 Aug 2019 Status changed from active, no longer recruiting to completed.